反对批准阿尔茨海默症药物，2名美国FDA专家辞职_老虎社区_美港股上老虎

反对批准阿尔茨海默症药物，2名美国FDA专家辞职

央视2021-06-10

据美国媒体于当地时间6月10日报道，因反对美国食物和药物管理局（FDA）批准美国Biogen公司生产的药物aducanumab用于治疗阿尔茨海默症，该机构咨询委员会的2名专家组成员决定辞职。投票反对批准的神经病学家戴维·诺普曼（David Knopman）和华盛顿大学神经病学家乔尔·佩尔穆特（ Joel Perlmutter ）相继辞去委员会的职务，并表示对美国食物和药物管理局处理委员会意见的...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

赞我的今年账户翻十倍
·2021-06-11
有猫腻
回复
1
举报
Sam5208
·2021-06-11
😀😱😱
回复
2
举报
收起
- Nicolim:
  [What]
  2021-06-11
  回复
  举报

热议股票

7x24

全部

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

关注我们

{"i18n":{"language":"zh_CN"},"data":{"share":"https://www.laohu8.com/m/news/2142522280?lang=zh_CN&edition=full","thumbnail":"https://static.tigerbbs.com/d17cb0ea313437e7afb8bad7f25dce9a","is_english":false,"pubTime":"2021-06-10 23:46","share_image_url":"https://static.laohu8.com/b0d1b7e8843deea78cc308b15114de44","id":"2142522280","market":"hk","top_or_hot":-1,"title":"反对批准阿尔茨海默症药物，2名美国FDA专家辞职","media":"央视","content":"<div>\n<p>据美国媒体于当地时间6月10日报道，因反对美国食物和药物管理局（FDA）批准美国Biogen公司生产的药物aducanumab用于治疗阿尔茨海默症，该机构咨询委员会的2名专家组成员决定辞职。\n投票反对批准的神经病学家戴维·诺普曼（David Knopman）和华盛顿大学神经病学家乔尔·佩尔穆特（ Joel Perlmutter ）相继辞去委员会的职务，并表示对美国食物和药物管理局处理委员会意见的...</p>\n\n<a href=\"https://finance.sina.com.cn/roll/2021-06-11/doc-ikqcfnca0342680.shtml\">网页链接</a>\n\n</div>\n","source":"sina","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>反对批准阿尔茨海默症药物，2名美国FDA专家辞职</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n反对批准阿尔茨海默症药物，2名美国FDA专家辞职\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-10 23:46 北京时间&nbsp;&nbsp;&nbsp;<a href=https://finance.sina.com.cn/roll/2021-06-11/doc-ikqcfnca0342680.shtml><strong>央视</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>据美国媒体于当地时间6月10日报道，因反对美国食物和药物管理局（FDA）批准美国Biogen公司生产的药物aducanumab用于治疗阿尔茨海默症，该机构咨询委员会的2名专家组成员决定辞职。\n投票反对批准的神经病学家戴维·诺普曼（David Knopman）和华盛顿大学神经病学家乔尔·佩尔穆特（ Joel Perlmutter ）相继辞去委员会的职务，并表示对美国食物和药物管理局处理委员会意见的...</p>\n\n<a href=\"https://finance.sina.com.cn/roll/2021-06-11/doc-ikqcfnca0342680.shtml\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":"https://finance.sina.com.cn/roll/2021-06-11/doc-ikqcfnca0342680.shtml","article_id":"2142522280","we_media_id":null,"thumbnails":["https://static.tigerbbs.com/d17cb0ea313437e7afb8bad7f25dce9a"],"rights":{"source":"sina","url":"https://finance.sina.com.cn/roll/2021-06-11/doc-ikqcfnca0342680.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2142522280","pubTimestamp":1623339960,"sourceInfo":{"source_id":"sina","name":"sina"},"weMediaInfo":null,"summary":"　　据美国媒体于当地时间6月10日报道，因反对美国食物和药物管理局 批准美国Biogen公司生产的药物aducanumab用于治疗阿尔茨海默症，该机构咨询委员会的2名专家组成员决定辞职。6月7日美国食物和药物管理局决定“加速批准”该药物，使其成为美国监管机构批准的第一种减缓阿尔茨海默症患者认知能力下降的药物，也是近20年来首款治疗该疾病的新药。","collect":0,"end_time":0,"defaultTopTitle":"sina.com.cn","property":[],"viewcount":null,"language":"zh","relate_stocks":{},"translate_title":"Opposing the approval of Alzheimer's drugs, two US FDA experts resigned","themeId":null,"isJumpTheme":false,"ttsUrl":"https://static.tigerbbs.com/418833555527eb4a037f42203eedf858","symbols_score_info":{},"content_text":"据美国媒体于当地时间6月10日报道，因反对美国食物和药物管理局（FDA）批准美国Biogen公司生产的药物aducanumab用于治疗阿尔茨海默症，该机构咨询委员会的2名专家组成员决定辞职。\n投票反对批准的神经病学家戴维·诺普曼（David Knopman）和华盛顿大学神经病学家乔尔·佩尔穆特（ Joel Perlmutter ）相继辞去委员会的职务，并表示对美国食物和药物管理局处理委员会意见的方式感到失望。\n2020年11月，美国食物和药物管理局曾拒绝批准该药物，当时咨询委员会中的11名成员几乎一致投票否定，理由是没有确凿的证据证明该药物有效。6月7日美国食物和药物管理局决定“加速批准”该药物，使其成为美国监管机构批准的第一种减缓阿尔茨海默症患者认知能力下降的药物，也是近20年来首款治疗该疾病的新药。（央视记者 刘旭）","kind":null,"is_publish_news":false,"is_publish_highlight":false,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[{"id":181364145,"gmtCreate":1623374737687,"gmtModify":1634034045668,"author":{"id":"3569581951650623","authorId":"3569581951650623","name":"赞我的今年账户翻十倍","avatar":"https://static.tigerbbs.com/d1d63378f07d4231f465c7cd27356410","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"有猫腻","listText":"有猫腻","text":"有猫腻","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/181364145","repostId":2142522280,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":181024342,"gmtCreate":1623368294286,"gmtModify":1634034211414,"author":{"id":"3581848994911851","authorId":"3581848994911851","name":"Sam5208","avatar":"https://static.tigerbbs.com/586c65cc720cf02feaa5e899bdcca358","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"😀😱😱","listText":"😀😱😱","text":"😀😱😱","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/181024342","repostId":2142522280,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4673994,"gmtCreate":1623368863512,"gmtModify":1635328745177,"authorId":3579856901836548,"author":{"id":3579856901836548,"authorId":3579856901836548,"name":"Nicolim","avatar":"https://static.tigerbbs.com/80b0baf2cddc7180a9960d23753f6148","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":181024342,"type":1,"supId":0,"prevId":0,"content":"[What]","text":"[What]","html":"[What]"}],"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":10,"commentSize":2,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}